Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment.

SunYoung Rha, Hei Cheul Jeung, Jae Kyung Roh, Jin Ju Kim, Sung Hoon Noh, Jin Sik Min, Byung Soo Kim, Hyuncheol Chung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Among the many biological characteristics of cancer, matrix-metalloproteinases (MMPs) are essential for tumor invasion and metastasis. To test the possibility of ex vivo model as a therapeutic guideline for MMP inhibitor (MMPI) treatment, we evaluated IC50 of the gabexate mesylate against MMP-9. Thirty-four paired normal and gastric cancer tissues were tested to measure the IC50 of the gabexate mesylate. MMP-9 activity was measured by zymography. Both MMP-9 expression (p=0.04) and IC50 (p=0.02) were higher in cancer than normal tissues. IC50 of the cancer tissues was higher than paired normal tissues especially in cases with large tumor (> or =5 cm) (p=0.03), higher T-stage (p=0.04), lymph node metastasis (p=0.04) and advanced stage (p=0.04). In cancers extending beyond submucosa or in diffuse/mixed type, a tendency of higher IC50 was observed than tumors confined to submucosa or intestinal type cancer despite similar MMP-9 activity between the groups. Patients with high IC50 showed poorer prognosis than patients with low IC50 in curatively-resected group. In multivariate analysis, high IC50 was suggested as an independent prognostic factor. We were able to differentiate the high risk patients using IC50 of gabexate mesylate in ex vivo model. This model can be applied in detecting patients with poor prognosis and patients who may benefit from MMPI treatment.

Original languageEnglish
Pages (from-to)251-256
Number of pages6
JournalInternational journal of molecular medicine
Volume10
Issue number3
Publication statusPublished - 2002 Jan 1

Fingerprint

Matrix Metalloproteinase Inhibitors
Inhibitory Concentration 50
Stomach Neoplasms
Phenotype
Gabexate
Matrix Metalloproteinase 9
Neoplasms
Therapeutics
Neoplasm Metastasis
Intestinal Neoplasms
Matrix Metalloproteinases
Multivariate Analysis
Lymph Nodes
Guidelines

All Science Journal Classification (ASJC) codes

  • Genetics

Cite this

Rha, SunYoung ; Jeung, Hei Cheul ; Roh, Jae Kyung ; Kim, Jin Ju ; Noh, Sung Hoon ; Min, Jin Sik ; Kim, Byung Soo ; Chung, Hyuncheol. / Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. In: International journal of molecular medicine. 2002 ; Vol. 10, No. 3. pp. 251-256.
@article{47133f1b2a044ddab15885e950ad8a47,
title = "Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment.",
abstract = "Among the many biological characteristics of cancer, matrix-metalloproteinases (MMPs) are essential for tumor invasion and metastasis. To test the possibility of ex vivo model as a therapeutic guideline for MMP inhibitor (MMPI) treatment, we evaluated IC50 of the gabexate mesylate against MMP-9. Thirty-four paired normal and gastric cancer tissues were tested to measure the IC50 of the gabexate mesylate. MMP-9 activity was measured by zymography. Both MMP-9 expression (p=0.04) and IC50 (p=0.02) were higher in cancer than normal tissues. IC50 of the cancer tissues was higher than paired normal tissues especially in cases with large tumor (> or =5 cm) (p=0.03), higher T-stage (p=0.04), lymph node metastasis (p=0.04) and advanced stage (p=0.04). In cancers extending beyond submucosa or in diffuse/mixed type, a tendency of higher IC50 was observed than tumors confined to submucosa or intestinal type cancer despite similar MMP-9 activity between the groups. Patients with high IC50 showed poorer prognosis than patients with low IC50 in curatively-resected group. In multivariate analysis, high IC50 was suggested as an independent prognostic factor. We were able to differentiate the high risk patients using IC50 of gabexate mesylate in ex vivo model. This model can be applied in detecting patients with poor prognosis and patients who may benefit from MMPI treatment.",
author = "SunYoung Rha and Jeung, {Hei Cheul} and Roh, {Jae Kyung} and Kim, {Jin Ju} and Noh, {Sung Hoon} and Min, {Jin Sik} and Kim, {Byung Soo} and Hyuncheol Chung",
year = "2002",
month = "1",
day = "1",
language = "English",
volume = "10",
pages = "251--256",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "3",

}

Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. / Rha, SunYoung; Jeung, Hei Cheul; Roh, Jae Kyung; Kim, Jin Ju; Noh, Sung Hoon; Min, Jin Sik; Kim, Byung Soo; Chung, Hyuncheol.

In: International journal of molecular medicine, Vol. 10, No. 3, 01.01.2002, p. 251-256.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment.

AU - Rha, SunYoung

AU - Jeung, Hei Cheul

AU - Roh, Jae Kyung

AU - Kim, Jin Ju

AU - Noh, Sung Hoon

AU - Min, Jin Sik

AU - Kim, Byung Soo

AU - Chung, Hyuncheol

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Among the many biological characteristics of cancer, matrix-metalloproteinases (MMPs) are essential for tumor invasion and metastasis. To test the possibility of ex vivo model as a therapeutic guideline for MMP inhibitor (MMPI) treatment, we evaluated IC50 of the gabexate mesylate against MMP-9. Thirty-four paired normal and gastric cancer tissues were tested to measure the IC50 of the gabexate mesylate. MMP-9 activity was measured by zymography. Both MMP-9 expression (p=0.04) and IC50 (p=0.02) were higher in cancer than normal tissues. IC50 of the cancer tissues was higher than paired normal tissues especially in cases with large tumor (> or =5 cm) (p=0.03), higher T-stage (p=0.04), lymph node metastasis (p=0.04) and advanced stage (p=0.04). In cancers extending beyond submucosa or in diffuse/mixed type, a tendency of higher IC50 was observed than tumors confined to submucosa or intestinal type cancer despite similar MMP-9 activity between the groups. Patients with high IC50 showed poorer prognosis than patients with low IC50 in curatively-resected group. In multivariate analysis, high IC50 was suggested as an independent prognostic factor. We were able to differentiate the high risk patients using IC50 of gabexate mesylate in ex vivo model. This model can be applied in detecting patients with poor prognosis and patients who may benefit from MMPI treatment.

AB - Among the many biological characteristics of cancer, matrix-metalloproteinases (MMPs) are essential for tumor invasion and metastasis. To test the possibility of ex vivo model as a therapeutic guideline for MMP inhibitor (MMPI) treatment, we evaluated IC50 of the gabexate mesylate against MMP-9. Thirty-four paired normal and gastric cancer tissues were tested to measure the IC50 of the gabexate mesylate. MMP-9 activity was measured by zymography. Both MMP-9 expression (p=0.04) and IC50 (p=0.02) were higher in cancer than normal tissues. IC50 of the cancer tissues was higher than paired normal tissues especially in cases with large tumor (> or =5 cm) (p=0.03), higher T-stage (p=0.04), lymph node metastasis (p=0.04) and advanced stage (p=0.04). In cancers extending beyond submucosa or in diffuse/mixed type, a tendency of higher IC50 was observed than tumors confined to submucosa or intestinal type cancer despite similar MMP-9 activity between the groups. Patients with high IC50 showed poorer prognosis than patients with low IC50 in curatively-resected group. In multivariate analysis, high IC50 was suggested as an independent prognostic factor. We were able to differentiate the high risk patients using IC50 of gabexate mesylate in ex vivo model. This model can be applied in detecting patients with poor prognosis and patients who may benefit from MMPI treatment.

UR - http://www.scopus.com/inward/record.url?scp=0036725924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036725924&partnerID=8YFLogxK

M3 - Article

C2 - 12165796

AN - SCOPUS:0036725924

VL - 10

SP - 251

EP - 256

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 3

ER -